ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
June 20, 2017 08:30 ET
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA ...
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
May 15, 2017 08:30 ET
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., May 15, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...